|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular & Cellular Proteomics 4:523-533, 2005.
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc.


,¶
,||
From the
GI Division/Department of Medicine, University of Washington, Seattle, WA 98195;
Institute for Systems Biology, Seattle, WA 98103; and || Institute for Molecular Systems Biology, ETH Zurich and Faculty of Nature, Science Federal Institute, University of Zurich, CH-8093 Zurich, Switzerland
Pancreatic cancer is a uniformly lethal disease that is difficult to diagnose at early stage and even more difficult to cure. In recent years, there has been a substantial interest in applying proteomics technologies to identify protein biomarkers for early detection of cancer. Quantitative proteomic profiling of body fluids, tissues, or other biological samples to identify differentially expressed proteins represents a very promising approach for improving the outcome of this disease. Proteins associated with pancreatic cancer identified through proteomic profiling technologies could be useful as biomarkers for the early diagnosis, therapeutic targets, and disease response markers. In this article, we discuss recent progress and challenges for applying quantitative proteomics technologies for biomarker discovery in pancreatic cancer.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
X. Yi, J. M. Luk, N. P. Lee, J. Peng, X. Leng, X.-Y. Guan, G. K. Lau, L. Beretta, and S.-T. Fan Association of Mortalin (HSPA9) with Liver Cancer Metastasis and Prediction for Early Tumor Recurrence Mol. Cell. Proteomics, February 1, 2008; 7(2): 315 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Hammoud, L. Dobrolecki, K. A. Kesler, E. Rahmani, K. Rieger, L. H. Malkas, and R. J. Hickey Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern Ann. Thorac. Surg., August 1, 2007; 84(2): 384 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chen, T. A. Brentnall, S. Pan, K. Cooke, K. W. Moyes, Z. Lane, D. A. Crispin, D. R. Goodlett, R. Aebersold, and M. P. Bronner Quantitative Proteomics Analysis Reveals That Proteins Differentially Expressed in Chronic Pancreatitis Are Also Frequently Involved in Pancreatic Cancer Mol. Cell. Proteomics, August 1, 2007; 6(8): 1331 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ortiz-Zapater, S. Peiro, O. Roda, J. M. Corominas, S. Aguilar, C. Ampurdanes, F. X. Real, and P. Navarro Tissue Plasminogen Activator Induces Pancreatic Cancer Cell Proliferation by a Non-Catalytic Mechanism That Requires Extracellular Signal-Regulated Kinase 1/2 Activation through Epidermal Growth Factor Receptor and Annexin A2 Am. J. Pathol., May 1, 2007; 170(5): 1573 - 1584. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. H. Ryu, J. C. Atkinson, G. T. Hoehn, G. G. Illei, and T. C. Hart Identification of parotid salivary biomarkers in Sjogren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis Rheumatology, September 1, 2006; 45(9): 1077 - 1086. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Journal of Lipid Research | ASBMB Today |